Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 280-285

  Zhou, Qing Hui ^a   Fu, Ailing ^a   Boado, Ruben J ^a,b   Hui, Eric Ka Wai ^b   Lu, Jeff Zhiqiang ^b   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ArmaGen Technologies Inc   (United States)

Author keywords

Alzheimer's disease; Amyloid; Blood brain barrier; Drug targeting; Monoclonal antibody

Indexed keywords

ABETA AMYLOID ANTIBODY; AMYLOID BETA PROTEIN; CHIMERIC TRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SODIUM CHLORIDE; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY ENGINEERING; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; DRUG PENETRATION; DRUG TARGETING; HEAVY CHAIN; HORSE; IMMUNOHISTOCHEMISTRY; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; RECEPTORS, TRANSFERRIN;

EID: 79952932382     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1003515     Document Type: Article

References (31)

1. Cummings, B. J.; Cotman, C. W. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 1995, 346 (8989), 1524-8. (Pubitemid 3006327)
2. Naslund, J.; Haroutunian, V.; Mohs, R.; Davis, K. L.; Davies, P.; Greengard, P.; Buxbaum, J. D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, J. Am. Med. Assoc. 2000, 283 (12), 1571-7. (Pubitemid 30161512)
3. Glenner, G. G.; Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120 (3), 885-90. (Pubitemid 14104991)
4. Masters, C. L.; Simms, G.; Weinman, N. A.; Multhaup, G.; McDonald, B. L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82 (12), 4245-9. (Pubitemid 15053619)
5. Lombardo, J. A.; Stern, E. A.; McLellan, M. E.; Kajdasz, S. T.; Hickey, G. A.; Bacskai, B. J.; Hyman, B. T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 2003, 23, 10879-83. (Pubitemid 37499696)
6. Brendza, R. P.; Bacskai, B. J.; Cirrito, J. R.; Simmons, K. A.; Skoch, J. M.; Klunk, W. E.; Mathis, C. A.; Bales, K. R.; Paul, S. M.; Hyman, B. T.; Holtzman, D. M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 2005, 115 (2), 428-33. (Pubitemid 40385484)
7. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6 (8), 916-9. (Pubitemid 30644751)
8. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Dodart, J. C.; Paul, S. M.; Holtzman, D. M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (15), 8850-5. (Pubitemid 32678116)
9. Wilcock, D. M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M. J.; Gordon, M. N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24 (27), 6144-51. (Pubitemid 38891105)
10. Seubert, P.; Barbour, R.; Khan, K.; Motter, R.; Tang, P.; Kholodenko, D.; Kling, K.; Schenk, D.; Johnson-Wood, K.; Schroeter, S.; Gill, D.; Jacobsen, J. S.; Pangalos, M.; Basi, G.; Games, D. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis. 2008, 5 (2), 65-71.
11. Boado, R. J.; Zhang, Y.; Xia, C. F.; Pardridge, W. M. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjugate Chem. 2007, 18 (2), 447-55. (Pubitemid 46493516)
12. Pardridge, W. M. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimer's Dementia 2009, 5 (5), 427-32.
13. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P. M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298 (5597), 1379. (Pubitemid 35346131)
14. Wilcock, D. M.; Alamed, J.; Gottschall, P. E.; Grimm, J.; Rosenthal, A.; Pons, J.; Ronan, V.; Symmonds, K.; Gordon, M. N.; Morgan, D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26 (20), 5340-6. (Pubitemid 44318386)
15. Talan, J. High-Dose Bapineuzumab puts some AD patients at risk for vasogenic cerebral edema. Neurol. Today 2009, 9 (10), 4.
16. Pardridge, W. M.; Kang, Y. S.; Buciak, J. L.; Yang, J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 1995, 12, 807-16.
17. Boado, R. J.; Zhang, Y.; Wang, Y.; Pardridge, W. M. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 2009, 102, 1251-8.
18. Boado, R. J.; Zhou, Q. H.; Lu, J. Z.; Hui, E. K.; Pardridge, W. M. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharmaceutics 2010, 7, 237-44.
19. Lee, H. J.; Engelhardt, B.; Lesley, J.; Bickel, U.; Pardridge, W. M. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J. Pharmacol. Exp. Ther. 2000, 292, 1048-52. (Pubitemid 30136600)
20. Jankowsky, J. L.; Slunt, H. H.; Ratovitski, T.; Jenkins, N. A.; Copeland, N. G.; Borchelt, D. R. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 2001, 17 (6), 157-65. (Pubitemid 32409891)
21. Pardridge, W. M.; Boado, R. J. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm. Res. 2009, 26 (10), 2227-36.
22. Hinton, P. R.; Johlfs, M. G.; Xiong, J. M.; Hanestad, K.; Ong, K. C.; Bullock, C.; Keller, S.; Tang, M. T.; Tso, J. Y.; Vasquez, M.; Tsurushita, N. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 2004, 279 (8), 6213-6. (Pubitemid 38248752)
23. LeBastard, N.; Aerts, L.; Leurs, J.; Blomme, W.; DeDeyn, P. P.; Engelborghs, S. No correlation between time-linked plasma and CSF Aβ levels. Neurochem. Int. 2009, 55, 820-5.
24. Su, G. C.; Arendash, G. W.; Kalaria, R. N.; Bjugstad, K. B.; Mullan, M. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 1999, 818 (1), 105-17. (Pubitemid 29227289)
25. Jancso, G.; Domoki, F.; Santha, P.; Varga, J.; Fischer, J.; Orosz, K.; Penke, B.; Becskei, A.; Dux, M.; Toth, L. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci. Lett. 1998, 253 (2), 139-41. (Pubitemid 28430642)
26. Boado, R. J.; Lu, J. Z.; Hui, E. K.; Pardridge, W. M. IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. Biotechnol. Bioeng. 2010, 105 (3), 627-35.
27. De Groot, A. S.; Moise, L.; McMurry, J. A.; Wambre, E.; Van Overtvelt, L.; Moingeon, P.; Scott, D. W.; Martin, W. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008, 112 (8), 3303-11.
28. Janelsins, M. C.; Mastrangelo, M. A.; Park, K. M.; Sudol, K. L.; Narrow, W. C.; Oddo, S.; LaFerla, F. M.; Callahan, L. M.; Federoff, H. J.; Bowers, W. J. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol. 2008, 173 (6), 1768-82.
29. McAlpine, F. E.; Lee, J. K.; Harms, A. S.; Ruhn, K. A.; Blurton-Jones, M.; Hong, J.; Das, P.; Golde, T. E.; LaFerla, F. M.; Oddo, S.; Blesch, A.; Tansey, M. G. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol, Dis. 2009, 34 (1), 163-77.
30. Boado, R. J.; Hui, E. K.; Lu, J. Z.; Zhou, Q. H.; Pardridge, W. M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 2010, 146 (1-2), 84-91.
31. Zhou, Q. H.; Boado, R. J.; Hui, E. K.; Lu, J. Z.; Pardridge, W. M. Brain-Penetrating TNFR Decoy Receptor in the Mouse. Drug Metab. Dispos. 2011, 39, 71-76.